Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Recurrent Miscarriage Clinical Trial

— FaCIL-2  

Official title:

Regulatory T-cell Induction by Low-dose Interleukin-2 in Women With Unexplained Repeated Spontaneous Early Miscarriages

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03970954
• Other study ID #: APHP 180256
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 5, 2021
• Est. completion date: March 20, 2024

Study information

• Verified date: May 2024
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.

Description:

About 1 to 3% of women of childbearing age have repeated early spontaneous miscarriages that may be related to parental chromosomal abnormalities, uterine abnormalities, hormonal causes, infectious etiology, thrombophilia ... When one of these known causes is excluded, it is unexplained miscarriages of which half would be due to an immunological deregulation of the mother causing a decrease of the tolerance to the fetus.

In this context, the stimulation of regulatory T cells (Tregs) by low dose IL-2 is a therapeutic option with a rational, preclinical and clinical data very favorable.

In humans, low dose IL-2 allows preferential activation of Tregs and is very well tolerated. Several therapeutic trials have shown its efficiencies.

These elements make it possible to envisage the development of a therapeutic to prevent fetal rejection by IL2-fd on the women with spontaneous miscarriages by an immunological deregulation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: March 20, 2024
• Est. primary completion date: July 28, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Woman with at least 5 consecutive early miscarriages less than 14 weeks of amenorrhea and unexplained after the usual check-up;

• Volunteer to participate in the trial and having given written consent after appropriate information.

Exclusion Criteria:

• Uterine or pelvic abnormality: uterine malformation, intracavitary fibroid, synechiae, polyp, hydrosalpinx;

• Balanced translocations in both spouses;

• Diabetes type I or II;

• Sickle cell disease;

• Contraindication to pregnancy;

• Constitutional or acquired thrombophilia (protein deficit C, S, ATIII, homozygous factor V or II deficiency, antiphospholipid syndrome, antithyroid antibodies positive, celiac disease, hyperhomocysteinemia);

• Ovarian insufficiency (AMH <1 ng/ml); AFC < 4

• Significant spermogram abnormalities and DNA fragmented more than 30%

• Active HIV or HCV infection;

• Main known contraindications to treatment with IL-2:

• Hypersensitivity to the active substance or to any of the excipients;

• Signs of progressive infection requiring antibiotic therapy;

• History of organ allograft;

• Pre-existing autoimmune disease;

• Leukocytes <4000 / mm3; platelets <100,000 / mm3; hematocrit <30%;

• hepatic or renal insufficiency;

• depression;

• significant history or existence of a serious heart disease (in doubtful cases, perform a stress test);

• patients with autoimmune disease;

• patients with an infection (septicemia, bacterial endocarditis, septic thrombophlebitis, peritonitis and pneumonia);

• pregnancy;

• Treatment with immunomodulators, immunosuppressants (class L04A of the ATC classification), in particular systemic corticosteroids, as well as aspirin and low molecular weight heparin;

• No affiliation to a social security;

• Person who has already been included in this study or in another at the same time;

• Major incapacitated patient (tutorship / curatorship);

• Patient with an allergy to taking IL2-fd;

• Participants who would present professional risk factors (eg ionizing exposure);

Related Conditions & MeSH terms

• Abortion, Habitual
• Abortion, Spontaneous
• Recurrent Miscarriage

Intervention

Drug:
• low-dose IL-2
Subcutaneous injection of low dose of IL-2 for induction course of 5 days, the 10th day after the beginning of periods. At most 5 courses of low dose of IL-2.

Locations

Country	Name	City	State
France	Bornes	Paris	Hopital Tenon
France	Kayem	Paris	Hopital Trousseau
France	Mekinian	Paris	Hopital Saint Antoine

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Iltoo Pharma

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1]
Primary	Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Primary	Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Primary	Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Primary	Variation of rate of blood circulating T regulator lymphocytes(expressed in % of CD4 and total)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11
Secondary	Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 38 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Secondary	Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 66 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Secondary	Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 94 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Secondary	Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 122 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 1
Secondary	Variation of rate of blood circulating T regulator lymphocytes(expressed in absolute numbers)	Change of Tregs at Day 14 of cycles under low dose of IL-2 compared to the baseline of the first cycle without low dose of IL-2	At the day 150 of Cycle 2 (each cycle is 28 days) compared from the day 10 of Cycle 11